The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and ...

The current model for managing chronic obstructive pulmonary disease (COPD) generally considers inhalers from the same therapeutic class to be clinically equivalent.1 When a long-acting muscarinic ...

the right inhaler for the right person. There are various problems in administering asthma and COPD treatment to patients. In asthma, for example, people don't necessarily perceive that they have ...

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

Many inhalers that are vital for patients with asthma or COPD are associated with societal harms that can worsen the very diseases the products are designed to treat. How can this dilemma be resolved?

Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual condition management.

Inhalers are handheld devices that deliver ... making them important treatments for asthma and COPD. With Medicare, coverage for prescription drugs you take at home is available through Part ...

“This could influence treatment decisions and improve respiratory health in this high-risk population.” “GLP-1 medications might help lower COPD exacerbation risk by reducing systemic ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024More prescriptions filled through February ...

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 ...

The demand for inhalation and nasal spray generic drugs is growing as these medications provide affordable and effective treatment options for respiratory ailments like asthma, COPD, and allergies.